1.Prophylactic Phenylephrine for Iatrogenic Priapism: A Pilot Study With Peyronie's Patients.
Pengbo JIANG ; Athena CHRISTAKOS ; Mina FAM ; Hossein SADEGHI-NEJAD
Korean Journal of Urology 2014;55(10):665-669
PURPOSE: Although penile duplex Doppler ultrasonography (PDDU) is a common and integral procedure in a Peyronie's disease workup, the intracavernosal injection of vasoactive agents can carry a serious risk of priapism. Risk factors include young age, good baseline erectile function, and no coronary artery disease. In addition, patients with Peyronie's disease undergoing PDDU in an outpatient setting are at increased risk given the inability to predict optimal dosing. The present study was conducted to provide support for a standard protocol of early administration of phenylephrine in patients with a sustained erection after diagnostic intracavernosal injection of vasoactive agents to prevent the deleterious effects of iatrogenic priapism. MATERIALS AND METHODS: This was a retrospective review of Peyronie's disease patients who received phenylephrine reversal after intracavernosal alprostadil (prostaglandin E1) administration to look at the priapism rate. Safety was determined on the basis of adverse events reported by subjects and efficacy was determined on the basis of the rate of priapism following intervention. RESULTS: Patients with Peyronie's disease only had better hemodynamic values on PDDU than did patients with Peyronie's disease and erectile dysfunction. All of the patients receiving prophylactic phenylephrine had complete detumescence of erections without adverse events, including no priapism cases. CONCLUSIONS: The reversal of erections with phenylephrine after intracavernosal injections of alprostadil to prevent iatrogenic priapism can be effective without increased adverse effects.
Alprostadil/adverse effects/diagnostic use
;
Drug Evaluation/methods
;
Humans
;
Male
;
Middle Aged
;
Penile Erection
;
Penile Induration/*ultrasonography
;
Phenylephrine/*therapeutic use
;
Pilot Projects
;
Priapism/chemically induced/*prevention & control
;
Retrospective Studies
;
Ultrasonography, Doppler, Duplex/adverse effects/methods
;
Vasoconstrictor Agents/*therapeutic use
;
Vasodilator Agents/adverse effects/diagnostic use
2.The Adverse Events and Hemodynamic Effects of Adenosine-Based Cardiac MRI.
Thomas VOIGTLANDER ; Axel SCHMERMUND ; Peter BRAMLAGE ; Amelie ELSASSER ; Annett MAGEDANZ ; Hans Ulrich KAUCZOR ; Oliver K MOHRS
Korean Journal of Radiology 2011;12(4):424-430
OBJECTIVE: We wanted to prospectively assess the adverse events and hemodynamic effects associated with an intravenous adenosine infusion in patients with suspected or known coronary artery disease and who were undergoing cardiac MRI. MATERIALS AND METHODS: One hundred and sixty-eight patients (64 +/- 9 years) received adenosine (140 microg/kg/min) during cardiac MRI. Before and during the administration, the heart rate, systemic blood pressure, and oxygen saturation were monitored using a MRI-compatible system. We documented any signs and symptoms of potential adverse events. RESULTS: In total, 47 out of 168 patients (28%) experienced adverse effects, which were mostly mild or moderate. In 13 patients (8%), the adenosine infusion was discontinued due to intolerable dyspnea or chest pain. No high grade atrioventricular block, bronchospasm or other life-threatening adverse events occurred. The hemodynamic measurements showed a significant increase in the heart rate during adenosine infusion (69.3 +/- 11.7 versus 82.4 +/- 13.0 beats/min, respectively; p < 0.001). A significant but clinically irrelevant increase in oxygen saturation occurred during adenosine infusion (96 +/- 1.9% versus 97 +/- 1.3%, respectively; p < 0.001). The blood pressure did not significantly change during adenosine infusion (systolic: 142.8 +/- 24.0 versus 140.9 +/- 25.7 mmHg; diastolic: 80.2 +/- 12.5 mmHg versus 78.9 +/- 15.6, respectively). CONCLUSION: This study confirms the safety of adenosine infusion during cardiac MRI. A considerable proportion of all patients will experience minor adverse effects and some patients will not tolerate adenosine infusion. However, all adverse events can be successfully managed by a radiologist. The increased heart rate during adenosine infusion highlights the need to individually adjust the settings according to the patient, e.g., the number of slices of myocardial perfusion imaging.
Adenosine/administration & dosage/*adverse effects
;
Adult
;
Aged
;
Aged, 80 and over
;
Blood Pressure/drug effects
;
Contrast Media/diagnostic use
;
Coronary Disease/*diagnosis
;
Female
;
Gadolinium DTPA/diagnostic use
;
Heart Rate/drug effects
;
Hemodynamics
;
Humans
;
Infusions, Intravenous
;
*Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Oxygen/blood
;
Prospective Studies
;
Vasodilator Agents/administration & dosage/*adverse effects